 a Data presented are using the treatment-regimen estimand. b Tested for superiority and controlled for type I error. c Tested for superiority; controlled for type I error only for pooled tirzepatide vs insulin lispro. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes Original Investigation Research jama.com (Reprinted) JAMA November 7, 2023 Volume 330, Number 17 1637 © 2023 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by F. Hoffmann - La Roche LTD user on 10/02/2024lispro–treated participants reported new or worsening reti- nopathy confirmed by fundoscopic examination (Table 3). Significantincreasesinmeanpulseratereachedupto4.5 per minute with tirzepatide and 2.0 per minute with insulin lispro during the trial, with the difference in mean pulse rate from baseline ranging from 1.4 to 2.6 per minute with tirz- epatide compared with 1.0 per minute with insulin lispro at week 52 (eFigure 12A inSupplement 2 ). Tirzepatide treatment resulted in a significant decrease in mean systolic blood pressure (5.9-9.0 mm Hg) and diastolic blood pressure (1.0-3.3mmHg)vsnosignificantchangewithinsulinlisproat week 52 (eTable 7 and eFigure 12B-C inSupplement 2). Discussion Tirzepatide as an add-on to basal insulin treatment at indi- vidualandpooleddosesresultedinstatisticallyandclinically significantreductionsinmeanHbA1c andahigherpercentage of participants meeting an HbA1c target of less than 7.0%, Table 3.